Mptx2 defends against peritoneal infection by methicillin-resistant staphylococcus aureus

Area of Science:

• Infectious Diseases
• Immunology
• Microbiology

Background:

• Methicillin-resistant Staphylococcus aureus (MRSA) presents a growing challenge due to multi-drug resistance.
• Novel therapeutic strategies are urgently needed to combat MRSA infections.
• The biological function of Mucosal pentraxin 2 (Mptx2) remains largely uncharacterized.

Purpose of the Study:

• To investigate the role of Mptx2 in MRSA-associated peritoneal infections.
• To evaluate the antibacterial and anti-biofilm properties of Mptx2.
• To explore the mechanisms underlying Mptx2's action against MRSA.

Main Methods:

• In vitro assessment of Mptx2's antibacterial activity and biofilm inhibition.
• Macrophage phagocytosis assays to determine Mptx2's effect on immune cell function.
• In vivo evaluation of Mptx2 in a MRSA-induced peritonitis mouse model.

Main Results:

• Mptx2 significantly suppressed MRSA growth and biofilm formation in vitro.
• Mptx2 directly binds to MRSA, enhancing macrophage phagocytosis and clearance.
• In vivo, Mptx2 administration reduced MRSA burden and peritoneal damage, while Mptx2 knockout exacerbated injury.

Conclusions:

• Mptx2 exhibits potent bactericidal activity against MRSA in vitro and in vivo.
• Mptx2 represents a promising candidate for developing novel therapeutic approaches against MRSA peritonitis.
• Further research into Mptx2 could lead to new strategies for combating drug-resistant bacterial infections.